Celator Pharmaceuticals (CPXX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Celator® Pharmaceuticals Announces Third Quarter 2015 Financial Results and Business Update
November 12, 2015 4:05 PM ESTEWING, N.J., Nov. 12, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today reported business highlights and financial results for the third quarter ended September 30, 2015.
"The momentum builds as we continue to deliver on our milestones, from the induction response rate improvement observed in our Phase 3 study with VYXEOS (formerly CPX-351) and announced last quarter, to impressive results from data packages on novel combination programs," said Scott Jackson, Chief Executive Officer of the Company. "The external validation of our proprietary technologies, as evidenced with VYXEOS being selected as the... More
